Kennedy R. Lees
University of Glasgow
467 Papers
3.9K Citations
Kennedy R. Lees is an academic researcher from University of Glasgow. The author has contributed to research in topics: Stroke & Medicine. The author has an hindex of 86, co-authored 455 publications. Previous affiliations of Kennedy R. Lees include Ludwig Maximilian University of Munich & Cedars-Sinai Medical Center.
Chat about Author
Papers
Acute stroke and diabetes.
Kennedy R. Lees,Matthew Walters +1 more
TL;DR: Evidence from general patients treated in intensive care units suggests that intensive control of hyperglycaemia may improve early outcome and the European guidelines suggest that glucose control may be advisable and place a threshold of 10 mmol/l for definite intervention; American guidelines are weaker.
31
The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal Phase III study
Gilad Rosenberg,Natan M. Bornstein,Hans-Christoph Diener,Philip B. Gorelick,Ashfaq Shuaib,Kennedy R. Lees +5 more
TL;DR: This Phase III Membrane-Activated Chelator Stroke Intervention trial is based on promising data derived from previous Phase I and II DP-b99 trials and capitalizes on lessons learned from past stroke studies in relation to neuroprotection, patient selection and data analysis.
29
Will Delays in Treatment Jeopardize the Population Benefit From Extending the Time Window for Stroke Thrombolysis
Martin Pitt,Thomas Monks,Paritosh Agarwal,David Worthington,Gary A. Ford,Kennedy R. Lees,Ken Stein,Martin James +7 more
TL;DR: A Monte Carlo simulation showed that as this “deadline effect” increases, an extended treatment time window entails that an increasing number of patients are treated at a progressively lower absolute benefit to a point where the population benefit from extending the time window is entirely negated.
29
Early clinical experience with the novel NMDA receptor antagonist CNS 5161
TL;DR: This study suggests that CNS 5161 is well tolerated in healthy volunteers within the dose range studied, and studies to investigate the efficacy of the compound in man may now be justified.
29
Angiotensin-converting enzyme inhibitors in heart failure: Blood pressure changes after the first dose☆
TL;DR: A double-blind placebo-controlled study in a parallel group of patients with cardiac failure found that blood pressure responses differed between the groups, with a short-lived early fall after captopril and a long-lasting fall after enalapril whereas perindopril was no different from placebo.
29